Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Maria Cristina Budani, Stefania Fensore, Marco Di Marzio & Gian Mario Tiboni. (2021) Efficacy and safety of follitropin alpha biosimilars compared to their reference product: a Meta-analysis. Gynecological Endocrinology 37:5, pages 406-414.
Read now
Read now
Weiguang Xue, Adam Lloyd, Edel Falla, Claudia Roeder, Rudiger Papsch & Klaus Bühler. (2019) A cost-effectiveness evaluation of the originator follitropin alpha compared to the biosimilars for assisted reproduction in Germany. International Journal of Women's Health 11, pages 319-331.
Read now
Read now
Salvatore Gizzo, Marcos Ferrando, Monica Lispi, Claudio Ripellino, Nazarena Cataldo & Klaus Bühler. (2019) Reply: RE: a cost-effectiveness modeling evaluation comparing a biosimilar follitropin alfa preparation with its reference product for live birth outcome in Germany, Italy, and Spain. Journal of Medical Economics 22:4, pages 381-382.
Read now
Read now
Michaël Grynberg, Claire Murphy, Carole Doré, Laurence Fresneau, Ségolène Paillet, Nicoleta Petrica, Frédérique Maurel & Harinala Ravonimbola. (2019) A cost-effectiveness analysis comparing the originator follitropin alfa to its biosimilars in patients undergoing a medically assisted reproduction program from a French perspective. Journal of Medical Economics 22:1, pages 108-115.
Read now
Read now
Salvatore Gizzo, Marcos Ferrando, Monica Lispi, Claudio Ripellino, Nazarena Cataldo & Klaus Bühler. (2018) A cost-effectiveness modeling evaluation comparing a biosimilar follitropin alfa preparation with its reference product for live birth outcome in Germany, Italy and Spain. Journal of Medical Economics 21:11, pages 1096-1101.
Read now
Read now
Articles from other publishers (7)
R. Matorras, V.S. Chaudhari, C. Roeder, J.E. Schwarze, K. Bühler, K. Hwang, C. Chang-Woo, S. Iniesta, T. D‘Hooghe & R. Mathur. (2023) Evaluation of costs associated with fertility treatment leading to a live birth after one fresh transfer: A global perspective. Best Practice & Research Clinical Obstetrics & Gynaecology, pages 102349.
Crossref
Crossref
Juan-Enrique Schwarze, Christos Venetis, Silvia Iniesta, Edel Falla, Vasily Lukyanov, Elena de Agustin Calvo, Thomas D´Hooghe, Claudia Roeder & Roberto Matorras. (2022) Originator recombinant human follitropin alfa versus recombinant human follitropin alfa biosimilars in Spain: A cost-effectiveness analysis of assisted reproductive technology related to fresh embryo transfers. Best Practice & Research Clinical Obstetrics & Gynaecology 85, pages 203-216.
Crossref
Crossref
Loredana Bergandi, Stefano Canosa, Andrea Roberto Carosso, Carlotta Paschero, Gianluca Gennarelli, Francesca Silvagno, Chiara Benedetto & Alberto Revelli. (2020) Human Recombinant FSH and Its Biosimilars: Clinical Efficacy, Safety, and Cost-Effectiveness in Controlled Ovarian Stimulation for In Vitro Fertilization. Pharmaceuticals 13:7, pages 136.
Crossref
Crossref
Olga Delgado Sánchez, Daniel Ginard Vicens, Antonia Sampol Mayol & Josefa Terrasa Pons. (2019) Medicamentos biosimilares: impacto, oportunidades y estrategias. Doce años de experiencia en Europa. Medicina Clínica 152:10, pages 411-415.
Crossref
Crossref
Olga Delgado Sánchez, Daniel Ginard Vicens, Antonia Sampol Mayol & Josefa Terrasa Pons. (2019) Biosimilar medicines: Impact, opportunities and strategies. Twelve years of experience in Europe. Medicina Clínica (English Edition) 152:10, pages 411-415.
Crossref
Crossref
Gorka Barrenetxea, Juan Antonio García-Velasco, Belén Aragón, Jordi Osset, Max Brosa, Noemí López-Martínez & Buenaventura Coroleu. (2018) Comparative economic study of the use of corifollitropin alfa and daily rFSH for controlled ovarian stimulation in older patients: Cost-minimization analysis based on the PURSUE study. Reproductive Biomedicine & Society Online 5, pages 46-59.
Crossref
Crossref
Cristina Scavone, Liberata Sportiello, Liberato Berrino, Francesco Rossi & Annalisa Capuano. (2017) Biosimilars in the European Union from comparability exercise to real world experience: What we achieved and what we still need to achieve. Pharmacological Research 119, pages 265-271.
Crossref
Crossref